Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Vinpat, why did the shell guys from Miami get 4 million shares? Is that typical of a RTO?
Who orchestrated the whole Nemus going public proccess? Hollister or the current CFO?
I don't know why chico says 3 months
I don't think chico knows either. Chico! I mean no malice or harm. If you are making $$$ trading on the OTC, I think that is cool and wish you good luck.
But Since you won't be clear, I think you Are just shooting from Your mouth off. What was that website supposed to show? That NEMUS has a lot of competition? We trust the management to allocate capital to the most effective indications with the biggest market penetration potential. This is in addition to the main idea about investing in cannabinoid bio tech (molecules with medicinal efficacy that have been ignored due to social stigma/LOLwar on drugs). What else is there to say?
We discussed the UofM research on NB1111, what it was compared to in the studies, and that there are more effective medications out there. If that is your smoking gun, You have lost it.
And if your warning About dilution, there are some other boards where you are needed more than here. It could be necessary, but 20m USD is a lot of cash. CARA has 60m, ZYNE has 31m and NMUS has 20...
NMUS has made some mistakes (i.e their former CEO), but they just went to the Locker room and got a pretty big Bat.
Also, You Have been wrong before about NMUS. Remember that time you warned us about a reverse Split and the Schneider brothers exercising their options? Even though it Stated right in the release that if a r/s occured the exercise price would be adjusted? You are the boy who cried wolf.
A micro biologist in real life, that trades OTC stock in a alternate reality.
GLTFA
what clinical trials are you referring to? were pre-clinical here...
Meanwhile, chico is busy posting elsewhere: 'Slap the Ask SQUEEZE THE NAKED SHORTS'
If the thesis ever involves 'squeezing the shorts' get out, and fast
Vinpat is a smart guy.
Also, from what I gathered from a lecture by Dr. ElSohly, every plant has a different genetic profile. While obviously they will be similar, I'm not sure how your grow can meet dosage consistency requirements. ElSohly said you literally have to clone one plant over and over to deliver the exact same combination of whatever strain/combination of cannibinoids. Seems time and capital consuming.
Even in a interview, the TBP ceo admits 90+ percent of doctors are not going to prescribe a plant, or something derived from a plant.
So, ya, not sure why GW is so insistent on their GMP grows for their drugs. NMUS and ZYNE seem to have the right idea, both in terms of product consistent and cost of production.
Stock Price manipulation
Which is Really surprising given the quality of People involved here
Doubt it. The latest placement by Schneider's it states that the conversion price would be adjusted for any r/s in the future. For the other 1m+ warrants and options, you would have to dig up the initial agreements. It is a good question. But again, knowing NMUS has such good people, I'm sure they would protect shareholders from that.
As far as a strategy, I posted the requirements for NASDAQ and NYSE listings yesterday. It is anyone's guess how much resources will be devoted to it, while they pursue their CINV and glaucoma indications.
*if the halt is listed
I've been going through old Mad Money episodes and other coverage of GW.
I found Cannacord coverage from 2014 saying they think Sativex is likely to be approved by the FDA. Swing and a miss. If the drug is derived from the plant, is it automatically going to be Schedule 1'd? And if it is derived synthetically, can it avoid what I imagine is a costly Schedule 1 designation? What does it say about GW expertise with cannabis that they would take the time to develop a drug like Sativex?
More and more I'm taking to heart what Murphy has said about being a 'second-generation market disruptor'
I know Epidiolex is specifically designated for Dravet and Lennox-Gastaut syndromes, but they also have FDA fast track approval for childhood epilepsy, I read. Is Epidiolex being derived from the plant as well?
I know Morgan Stanley likes GW, I read they had been covering them since 2014. But, Vinpat, how much of GW's market cap has to do with theym getting pumped by Cramer on Mad Money a bunch of times? He even makes reference to the competitive advantage of them being in the UK and allowing to grow cannabis, since only Ol; Miss can grow it in the US. .
GLTFA
Ya, I thought so. It is kind amazing given that GWPH is the industry leader, that their first candidate would have a glaring flaw.
Does this show that NMUS has better expertise when it comes to cannibinoids....?
And isn't that why Sativex can't get FDA approval and is not that effective (re: bio availability)
I thought Vinpat said something like that...
Hmm, I wonder why NMUS went rectally instead of sublingually?
Won't they run into efficacy problems with the bioavailability of oral ingestion?
New research shows THC neuroprotective effects
https://www.fool.com/investing/2017/05/21/cannabis-impact-on-the-brain-in-this-new-study-sho.aspx
I noticed it says $INSY has a CINV drug in Phase 2. But it is correct that it is taken orally? With with we know about cannibinoids, how will they deal with the wide range of bioavailability? Are they stupid or something?
Requirements to uplist to Nasdaq or NYSE
Recently in a interview, CEO Murphy stated that with the proceeds from the Schneider private placement, 'aggressively look to uplist to either NYSE/Nasdaq'. Unlike a lot of OTC/micro-caps companies, when the CEO makes claims I tend to believe him. I wanted to know what is required from NMUS to make this a reality.
http://venturelawcorp.com/listing-requirements-nasdaq/
I don't know what '# Public Board Lot Holders' refers to. Market value (cap?) is 15m, with Schneider exercising their options NMUS is at 30m. But, stock price is something WAY off the requirements.
https://www.nyse.com/publicdocs/nyse/listing/NYSE_Initial_Listing_Standards_Summary.pdf
Similar story, with a bigger market cap required and a MUCH higher shareprice.
Although, I know plenty of securities that are traded on these exchanges with a share price $4>
Anyone have any thoughts or more info?
GLTFA
Nemus vs InMed IMO
I thought this was a good question and I have decided to give a response. Thank you to TrueTrades for highlighting my posts, but much more knowledgeable people on this board than me (my good friend Vinpat)
Disclosure: I bought IN.C between .20c – .40c CAD and sold between .70c-.80c CAD. I do not currently have a position in InMed.
I do have a position in $NMUS as of the time of this post.
$IMLFF has a market cap of 55m USD fully diluted (135m shares) v. $NMUS market cap of 30m fully diluted (105m shares).
IMLFF has roughly 2m USD cash v. NMUS with 20m USD cash
Neither have substantial liabilities.
If you look at Enterprise Value (MC+debt-cash) IMLFF has an EV of 53m v. NMUS 10m
So in terms of how the market is currently valuing these two companies, InMed is worth 1.5x-4x is worth more or is / that much more expensive to buy.
InMed $IMLFF $IN.C
I originally discovered InMed through their CEO Eric Adams interview on BNN (late 2016 early 2017). Clearly, the three things driving their value in the market is their ability to produce cannabinoids, cost-saving identification process of potential indications and their drug candidates.
I used to believe their bio-synthesis production (just like how insulin is produced by Eli Lilly) was going to be a disruptive technology in this space, once tier one players were ready to commercialize their drugs. Martin Bott, a Eli Lilly finance guy, being added to the board increased speculation around this. You can ask Vinpat, but I don’t think they have a patent on the way they produce cannabinoids. In addition, they have competition in this space. Teewinot is a private company with bio-synthesis cannabinoid tech and there are others.
Dr. Sazzad’s proprietary algorithms (bioinformatics) software is apparently another disruptive technology for the sector. Dr. Abu, who the poster mentioned worked at GWPH for a year or two, claimed in the Forbes article it is like nothing he has ever seen. I asked Nick Brusatore on Twitter about it; Brusatore, along with Dr. Hyder Khoja, started InMed. He said he had no idea if it was as special as they are now claiming it to be. I have a feeling other players have similar technology, but don’t bother including it as a ‘value driver’ of the company; to busy developing their drugs. As of now, I only know of RVV asking to license it out. I also think they deal fell apart (the term sheet has long expired without a word).
So, as far as bio-informatics and bio-synthesis, I came to realize I shouldn’t be placing much value on them as I originally had. And besides, we are talking about DRUG DEVELOPMENT. That is the most important thing here IMO. So what does InMed have in their pipeline?
Their lead candidate INM750 for EB is pre-clinical and there is no public data about its efficacy. Now, with what we know about cannabinoids, I do believe it will help EB patients. Cannabinoids have been known to have anti-bacterial properties. NMUS has a MRSA candidate, and even though KALYT is a shit show, they have another candidate related to a skin disease which looks promising. Their researching this with UBC and a university in Hungary (although that might be do with glaucoma).
As far as INM085, their glaucoma target, I think they are WAY behind NMUS in terms of the development process. If cannabinoids help glaucoma in a meaningful way, I don’t think IMLFF will be the ones to capitalize. You can also see they seem to more interested in pain/inflammation targets more than glaucoma judging by their last Investor Presentation. This wasn’t the case 6 months ago. And again, I have NO idea how well they have protected their intellectual property. This company was on life support just 18-24 months ago. Vinpat would know more about patents than me.
While I have voiced some of my concerns above, I could EASILY live with them and had continue to hold IMLFF. I am Canadian and patriotic; InMed is still the best cannabinoid drug development play in Canada. However, what began to concern me most is the PEOPLE involved. I bet Jockeys not Horses. So who are the jockeys at InMed?
Ostensibly, you have Eric Adams, Ado Muhammed, Sazzad Hossain and Paul Anderson as the faces of the company. Eric Adams, a successful track record and friendly gentleman. However, the more you dig the murky the waters get. Sazzad was successful developing/commercializing a drug with a +250m global market I believe and has been published many times in peer reviewed journals. He also has a relationship with the national research council in Canada. All good things; however, he has lent out his name before to other cannabis companies such as Affinor Growers. What did he share with $AFI?
Ado Muhhamed, yes, he worked at GWPH for a while. Can anyone tell me what he did there? Has anyone asked GW what tasks were involved in his role with the company? I don’t like how often InMed mention that he worked at GWPH in their press releases, while never discussing what he did.
Again, these discoveries weren’t THAT earth shattering and weren’t why I sold my position. There are some unanswered questions, but nothing dire. What ultimately lead me to sell was the behavior Chris Bogart and Craig Schneider, who happen to be the largest shareholders in $IMLFF:
Shareholders
Name Equities %
Christopher Bogart
7,774,572 14.7%
Craig D. Schneider
5,459,680 10.3%
Sazzad Hossain, PhD
3,000,000 5.67%
William J. Garner, MD
1,357,143 2.57%
Eric A. Adams
808,000 1.53%
Andrew Hull
625,000 1.18%
Adam D. Cutler
312,500 0.59%
James Maitland Macintosh
250,000 0.47%
Terese J. Gieselman
189,903 0.36%
Martin Bott
100,000 0.19%
People can go research these two gentleman and make up their own minds.
I’m tired of people shooting the messenger.
Schneider is now off of the board completely, but he is still the second largest shareholder and used to be the CEO. There is an interview with him somewhere on the Cannabis news network.
I noticed a user on Stockhouse who seemed to have an inside track of the company and was speaking with Schneider. He would says things like….
‘talked to Schneider after him leaving the board, he is not going anywhere just making room for the big players’
So I DM’d him to ask him more: Hey, what’s with the volatility in the SP?
‘Well, who do you think has been working it so hard?’ ?WORKING THE STOCK PRICE???WTF?
And then I get a message a few months ago from the same guy
‘Go buy SGH, going to be a 10 bagger!’
I look it up SGH.V...it’s a graphite company…I reply, why do I want to own a graphite company?
‘it won’t be a graphite company for long, look who owns it!’….(chris bogart)
So I reply, well…what’s it going to be?
‘sole supplier of cannabis for IMLFF and LP in Quebec’
I go ask a popular ‘Pot stock’ twitter account about SGH. He replies, ‘well, I don’t know anything but I participate in the private placement (0.05c/share) in January. YUCK! Dirty way to make a living.
Back in February, SGH stock price was trading between .06c to .08c CAD if it traded at all. It is now trading between .15c – .17c CAD with no PR or notice about a fundamental change. I don’t like this AT ALL. Scuzzy people float shells; very low energy stuff. What else are insiders telling their buddies and favorite investors?
Then it comes out they paid $25,000 and a few thousand shares for a pump, while their SP was already going off the charts. Wolf of Weed started tweeting about them on almost daily basis. All the same stuff over and over again: bio-synthesis, bioinformatics and their candidates. Too many red flags, too much shadiness and I don’t like the two largest shareholders. Their obviously successful people (I think Bogarts gold company Corex was bought by up by a bigger Gold company) but I REALLY don’t like how they operate. Eric Adams seems like a good guy, but he only has so much control. Bogart and Schneider own 25% of the company. Until their involvement has been significantly decreased, I’m not holding.
$NMUS
During my time on the IMLFF boards, I found this guy Vinpat. He had an edge to him and I like that. He also wasn’t buying the IMLFF pump; at first, I thought he was a hater. Then I realized he is just a smart guy who asks questions. He was talking about why NMUS is a better play in what I would call the ‘junior cannabinoid drug development’ sector. So I dug in about NMUS and a bunch others after I exited IMLFF. I went over $TRPX $OWCP $CNBX and $VBIO. I also considered $GWPH $ZYNE $CARA but am a young guy and am seeking ALPHA.
While I believe NMUS might have the best IP in the business, their market cap is dwarfed by the tier one players $GWPH $ZYNE and $CARA (I don’t count $INSY since there drugs kill people). The choice became quite clear as to what I wanted to hold as these companies begin trials and eventually commercialization of cannabinoid derived drugs. That is, if you believe there are drugs that could exist with efficacy that can be derived from cannabinoids.
First, and most important, it is the PEOPLE involved in NMUS as to why I sleep well at night holding. Now, chico might say something like ‘you never hold or get long on the OTC!’. I don’t day trade, I don’t flip or get short. I am long two names in two different sectors, that kind of concentration and my position size might make some of you vomit. I get that is risky, but it is the way I do business. But I am confident because of the PEOPLE. So, what people?
Brian Murphy used to be the CSO at $VRX before the Michael Pearson and Bill Ackman came in and destroyed the company. He has an impressive academic background and has been successful everywhere he goes. I tend to believe people don’t change (if you messed up back while running company A, you will probably drive company B into the ground too).
Mahmoud Elsohly has been researching cannabinoids since the 1970’s; I would encourage people to watch his lecture at the Justice Summit V (it is available on youtube) to understand how knowledgeable he is. He has been researching the possible pharmaceutical applications of this plant for over 40 years at the only school in the USA allowed to do so. It is an incredible competitive advantage to have his brain behind the development of NMUS candidates. He should be considered up there with Dr. Mech when considering the top cannabinoid academics.
I think Donald Abrams will be key in advancing their CINV drug. Not only his expertise with chemo patients, but the resources and connections he has to recruit patient populations for trials given his current positions. Cosmas Lykos, one of the founders, has been successful wherever he goes (Oakley).
And lastly, DOUG INGRAM. Go research him. Basically, he turned around Allergan (500m+ MC) while staving off a hostile take over by VRX. To be able to do that, look that big idiot Pearson in the face and say ‘NO YOU CAN’T BUY ME; and ‘I DON’T LIKE THE WAY YOU DO BUSINESS ASSHOLE’ while VRX market cap is the highest of ANY Canadian company….that takes guts and character.
These are the people involved with NMUS.; principled and track record of success.
NMUS has used different external companies to producer their candidates for pre-clinical research. Albany labs for synthetic, teewinot for bio-synthetic. I don’t know the difference between the two. Ask Vinpat. Regardless, they don’t seem to be concerned with spending time commercializing the production of cannabinoids like IMLFF or anyone else in the space.
As far as the technology involved in identifying potential indications for research, I have more confidence in the 40 years of academic research at U of Miss Pharma department than IMLFF bioinformatics. Time will tell who is right.
In terms of comparing their candidates, NMUS is very far ahead. Murphy has stated CINV could begin Phase 1 trials Q3-4 2017 and be fast tracked through Phase 2 trials because of its similarities to Marinol. Glaucoma (NB1111) has been patented throughout the globe, along with multiple delivery methods. Murphy has stated they believe Phase 1 trials will begin Q1 2018. U of M has published some of their research related to the efficacy of NB1111. Many good discussions have occurred on this board about their studies.
MRSA target NB3111 has some research out there and we already know about cannabinoids anti-infective properties. Vinpat and a few other people can talk about this better than me.
Dr. Abrams has some expertise with CIPN so he will be important with NB51R1. Again, other board members have more knowledge.
While $IMLFF and $NMUS both have large pipelines, I am more confident in NMUS. I think they have done MUCH more academic research into these targets, which goes back to the relationship with U of M being valuable.
Comparing the manipulation of the stock price of $NMUS and $IMLFF, I believe that the retail investor on the OTC is always going to be behind. The market makers are so few and far between; the lack of liquidity makes it very hard to get the best price when buy and selling on the exchange. When carving out my position, I rarely got filled at under the current stock price. I would have to bid between .0025c-.01c above the current price to get my order filled. But that has nothing to do with $NMUS, it just the reality of who is involved. Another example, two days before the Schneider brothers announcement, Cannacord shows up with a 250k bid at .25c…coincidence? Insiders are going to insider I guess. But, that is much different than $IMLFF where you have the big shareholders ‘market making’ themselves.
Important questions when thinking about your positions:
Who has the cash to take their target indications through trials?
Which shareholders are going to be faced with more dilution moving forward?
Who has more legitimate Stock Price catalysts in the next 12-24 months?
Who has a better relationship with the FDA which regulates the biggest drug market?
Which company offers better value in terms of today’s stock price, market cap and EV?
And most important, who has the better people involved in the company?
Individuals can decide for themselves. I will continue to follow the sector and my opinion is subject to change. And yes, I know about $IMLFF announcing a new raise with CannaLOLcord and Roth. Waiting to hear the dollar amount and the SP……
Thanks again to Vinpat, my man!
GLTFA and DYODD
Not 10m anymore. Fully diluted, including the latest private placement, there are roughly 105m shares outstanding.
So you market cap is roughly 30m.
So a 30m market cap, <1m in debt, and 20m in cash to fund two different candidates Phase 1 trials in the next 12 months (CINV and glaucoma)
Needless to say, Locked and Loaded
Thats what we think here
Undervalued is putting in mildly.
The IP and canidates best in class, or at least should be considered with the top tier guys $ZYNE $GWPH....and $INSY I guess....but $INSY makes drugs that kill people, so maybe just $ZYNE $GWPH $CARA
Even $IMLFF $VBIO $CNBX $KALTF have been enterprise values than us...
It is okay, my good friend Vinpat said we will win in the end. Good enough for me :)
Can you explain the difference between the two? The PR did first state HK and Japan were very important.
And while they did have patents approved before, I think these cover different applications of their THCVHS drug.
Dr. Mahmoud ElSohly, professor at the National Center for Natural Products Research (NCNPR) at the University of Mississippi commented: "The University is gratified to have years of innovative research recognized by a diverse number of territories globally. We look forward to continuing our relationship with Nemus to grow the patent estate not only related to the prodrug of THC and the analogue of CBD, but other types of cannabinoids as well."
Chico, I thought the relationship was falling apart??
It is almost like Someone was Messing around on the Halted exchange bids to induce Smart people to buy where it Wasnt halted....
They would need to exists to be photographed LDO
Look at th3 32k whack at the end of the day
Odds that Cannacord was messing around with thE SP? They do it a lot with $IMLFF
UGEIF Update
Dear Mr. Vinpat
I wouldn't even Bother with Guys like this
More chico's who Daytrade and Short OTC stocks for a Living
enjoy the weekend
what are you talking about?
$NMUS fun fact:
it is super easy to calc their fully diluted market cap now with the scheids bro deal. roughly 100 million shares, so just move the decimal place two to the right and add a M!
34.74m
How the development/research process for $ZYNE $GWPH or any other cannibis drug development company differ from InMed? Pretty sure those guys aren't throwin darts at a boards
If the biosynthesis tech InMed has superior to other companies like Teewinot, wouldn't InMed already have some revenues?
I wish them luck on their EB indication. Horrible disease. But I think they are late to the party on cannibis derived glaucoma indication.
And won't the company face further dilution when ramping up Phase I trials of their EB drug? If so, why are they bothering to waste money pumping their name on the internets?
GLTFA
Best of luck to your sir
Always remember
Day to day is just a mark
GLTFA
What are the odds this placement is real and actually closes?
Still waiting....
journaled my shares over from UGE.V to UGEIF because CAD dollar is getting killed
Does anyone know how exactly financing works. Can anyone model it?
People like Kent Deuters? He is worried about his rep? He has such a good one after $EAPH hired him to lead their venture into the cannabis industry. He did an amazing job!
cliff notes: Nothing happened for years, he mysteriously disappeared and Easton ended up suing the initial party that was supposed to help them enter the market.
John Simon? has anyone called Aurora to find out what he did there? Has anyone called John Simon to ask what he is doing for Vinergy?
Will Panenka? he also is a scientific director at abbatis. Not like there was ever a Pump and DUMP at $ATT. Very busy guy. Does his wife/sister/mom have private placement shares like with VIN?
And Core Capital Leading the Ship. They Have never been Involved with Anything shady.
You have Great people here
GLTFA
Ya I agree. With Honest people like Core Capital involved, I'm sure there is no way Anyone would try to find a way to sell on the OTC while their halted in Canada.
GLTFA
To be fair, the 30-40m number was found doing a google search for a few minutes. Drug development is unique.
I think CINV takes a lot less, glaucoma maybe more? VINPAT thoughts?
Don't think that has much to do with Luck my good friend Vinpat!
I wouldn't be to concerned. It has traded funny for me since I got constructive.
Despite what the current quote was, my bids were usually ignored, lower bids with smaller sizes getting filled.
5-10% swings shouldn't bother you and aren't a big deal to me.
Capital Not exactly that efficient on OTC. Ask Vinpat, NMUS doesn't get much respect. But they are Building things one piece at a time. Next 12 months will be a Fun wild Ride. Murphy and Co. know it is time to Execute
I'm not sure if I summarised this correctly, but go read the most recent 10K. This is what I took away from it.
In short, NMUS and UM (which is really just Elsohy's team) are very intertwined, have been for some time, and show no signs of wanting to break up. Particularly with them now possessing the funds to begin trials on multiple candidates, it appears Chico is just fear mongering without advertising his short position.
Kind like how he warned Schneider Bros's would exercise their right to .30c shares after a potential reverse split, even though it says RIGHT IN THE AGREEMENT any reverse split would be applied to the strike price
Dont feed trolls
DYODD
GLTFA
Vinpat is a good man
No, relationship with Teewinot. Read the last few releases, they are outsourcing it to a few people.
No, not trusting chico more than Murphy LOL
It was just frustrating to make a long summary post and call
For the discussion to get back to civilized
Only to see it get even worse
Oh well, like you said, the spotlight is on now so this was bound to happen
As long as you dont leave my good buddy Vinpat! That is most important
And LOL at the fears about UM and NMUS relationship falling apart. The MOU doesn't expire for a year, many of the IP is protected in perpetuity by NMUS, and everything else is So intertwined....it would make zero sense for their partnership to fall apart now...things are just starting to look up!